Analysts Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Price Target at $16.88

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been given an average rating of “Hold” by the six research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $16.8750.

A number of equities analysts have recently commented on HCM shares. Bank of America decreased their price target on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Wall Street Zen lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd.

Hedge Funds Weigh In On HUTCHMED

Large investors have recently modified their holdings of the company. Ameriprise Financial Inc. boosted its stake in HUTCHMED by 4.7% in the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of HUTCHMED by 5.9% in the 3rd quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock valued at $343,000 after purchasing an additional 1,209 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of HUTCHMED by 3.3% during the 4th quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock valued at $700,000 after purchasing an additional 1,680 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in shares of HUTCHMED by 12.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after purchasing an additional 1,873 shares during the last quarter. Finally, State Street Corp raised its position in HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares during the period. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Stock Performance

NASDAQ:HCM opened at $14.96 on Friday. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. The business’s 50-day moving average price is $14.59 and its two-hundred day moving average price is $14.77. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $19.50.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings data on Friday, March 6th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.50 by ($2.49). The company had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. As a group, equities research analysts predict that HUTCHMED will post 0.16 earnings per share for the current year.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.